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To investigate the durability of the first integrase inhibitor-based regimen in a HIV geriatric
multicentric prospective cohort and to explore the reasons of regimen discontinuation.
Design
This is an analysis conducted on the Geriatric Patients Living with HIV/AIDS (GEPPO)
cohort, an Italian prospective observational multicentre cohort of people living with HIV with
65 years of age or more.
Methods
The analysis was performed using R (version 4.0.2). The tests performed were two sided
assuming a 5% significance level (Kruskal-Wallis test, Chi-squared test, log-rank test and a
Cox Proportional Hazard model). The proportion of participants discontinuing the three regi-
mens was displayed using cumulative curves.
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Results
Among 1531 patients enrolled between 2017 and 2019 in the GEPPO cohort, we included
822 participants in this analysis. At baseline, median age was 69.8, the immunovirological
profile good, multimorbidity was present in 42.3% of participants, while 27.4% were on poly-
pharmacy. Overall, 483, 243 and 96 participants received DTG, RAL and EVG/c respec-
tively as first InSTI. At the end of the follow up 6.4%, 21.1% and 22.9% participants
discontinued DTG, RAL and EVG/c respectively. Using a log-rank test, EVG showed a sig-
nificantly lower durability than DTG (p<0.001) or RAL (p 0.05) or both, DTG and RAL
(p<0.001). Among participants who discontinued their regimen we found 0 virological failure
and 56.7% simplification/deprescription.
Conclusions
The three integrase inhibitors considered showed a good durability and no virological fail-
ures in geriatric patients such as those enrolled in the GEPPO cohort when used in a two or
three drug regimen.
Introduction
People living with HIV (PLWH) are aging, mainly for the longer life expectancy under effec-
tive combined antiretroviral therapy (cART) and the increasing age of newly diagnosed
patients [1, 2]. Geriatric populations (conventionally considered as people with 65 or more
years of age) present a peculiar pattern of health necessity. An integrated management is there-
fore needed to guarantee a healthy aging because PLWH have a higher risk of age-associated
events compared with the same non-HIV age cohorts [3]. For this reason a specific focus on
elderly PLWH is being implemented in several guidelines [4, 5].
Multimorbidity (i.e. the presence of at least 3 co-morbidities) is often present in elderly
PLWH and it is reported along with polypharmacy (i.e. the concomitant intake of at least 5
non-antiretroviral medications): both conditions have been associated with worse outcomes
[2, 6].
Moreover, there is a lack of randomized controlled trials (RCTs) designed properly to
investigate efficacy and toxicity of antiretrovirals in geriatric patients living with HIV. Recently
some sub-studies of RCTs including a�65 years old sub-group analysis were presented and
only one non-randomized single arm clinical trial showing good tolerability, safety profile and
immunovirological response with InSTI-based cART in geriatric PLWH both for cART expe-
rienced and naïve patients [7, 8].
One of the methods that may empirically show the tolerability of a drug regimen is its dura-
bility. Durability, defined as the time to regimen modification, depends on major outcomes
(e.g. allergic reactions, virological failure or drug-drug interactions) as well as on more subtle
factors such as mild side effects, the impact on quality of life, polypharmacy, comorbidities
and patients’ and physicians’ choice [9]. Integrase Strand Transfer Inhibitor (InSTI) contain-
ing regimens are the preferred treatment in naïve patients by several international guidelines:
the class includes raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and
bictegravir (BIC, only recently added to the armamentarium with very limited real-life data)
[4]. To date, no studies investigated the durability of InSTIs in geriatric PLWH. Therefore, in
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order to contribute filling the gap in current knowledge, we aimed to explore the durability of
InSTI-based regimens in a geriatric cohort of PLWH.
Methods
Participants were prospectively recruited between 2017 and 2019 from the Geriatric Patients
Living with HIV/AIDS (GEPPO) cohort, an Italian prospective observational multicentre
study characterising multimorbidity and geriatric syndromes in PLWH aged�65 years with a
special focus on cART prescription. Participants are followed according to clinical practice
and data about geriatric outcomes are recorded once a year. Regarding this study, inclusion
criteria was the initiation of first InSTI-based regimen after 2017. InSTIs included in the analy-
sis were DTG, RAL and EVG/c. Moreover, we explored the presence of multi-morbidity and
polypharmacy: those conditions have been previously defined and described in the GEPPO
cohort by Nozza et al [10].
Study primary endpoint was InSTI durability defined as time to discontinuation of first
InSTI regimen; we also analyzed the reason for cART discontinuation, categorized as: 1) viro-
logical failure, 2) simplification/deprescription, 3) others (including toxicity).
Statistical analysis
Continuous variables were described using median and interquartile range (IQR) while cate-
gorical variables were described with absolute frequencies and percentages. Comparisons of
continuous variables among InSTI regimes were performed using Kruskal-Wallis test while
Chi-squared test was used for categorical variables. The difference of InSTI discontinuation,
considered as the first regimen shift and modelled as a time-to-event variable, was tested
through a log-rank test and a Cox Proportional Hazard model adjusting by age, sex, multimor-
bidity (defined as the presence of at least 3 comorbidities) and the use of abacavir. The same
analysis was conducted for the subgroup on InSTI dual regimen. Median survival is defined as
the time needed for half of the participants in each regimen to discontinue the treatment. The
proportion of participants discontinuing the three regimens was displayed using cumulative
curves. All the test performed were two sided assuming a 5% significance level. All analyses
were performed using R (version 4.0.2).
Ethics statement
This study belongs to the GEPPO project. This project obtained approval by the Research Eth-
ics Board of each individual institute belonging to the GEPPO cohort. The Research Ethics
Board of the coordinating centre is the “Comitato Etico di Brescia”. All data were fully anon-
ymized before the statistical analysis was performed. Written informed consent was asked at
the first useful access.
Results
Among 1531 patients aged�65 years followed in the GEPPO cohort, we included 822 partici-
pants in this analysis. At baseline (defined as the time of inclusion in the analysis) median age
was 69.8 (IQR 7.4). Among study participants, 666 (81%) were males, the median CD4+ T-cell
count at baseline was 618 cell/μl (IQR 25–75: 437.5–814.0), and 95.2% had HIV RNA<50 cop-
ies/ml. Multimorbidity was present in 356 (43.3%) participants, while 225 (27.4%) were on
polypharmacy (all summary statistics are reported in Table 1).
Overall, 483, 243 and 96 participants received DTG, RAL and EVG/c respectively as first
InSTI. At the baseline, participants were on cART from a median (IQR 25–75) of 16.1 (10.3–
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Table 1. Overall and divided by first InSTI groups summary statistics of the variables considered in the study: Median and interquartile range are shown for contin-
uous variables while counts and percentages are considered for categorical variables. Kruskal-Wallis test and Chi-squared test were used for continuous and categorical
variables respectively.
DTG (N = 483) EVG (N = 96) RAL (N = 243) Total (N = 822) p value
Age (years) 0.020
Median (Q1, Q3) 69.8 (67.0, 74.4) 69.0 (66.3, 71.6) 70.6 (67.3, 75.6) 69.8 (67.0, 74.4)
Sex 0.645
Female 88 (18.2%) 15 (15.6%) 52 (21.4%) 155 (18.9%)
Male 394 (81.6%) 81 (84.4%) 191 (78.6%) 666 (81.0%)
Transgender 1 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.1%)
Multi-Morbidities (at least 3 comorbidities) 0.014
No 284 (58.8%) 62 (64.6%) 120 (49.4%) 466 (56.7%)
Yes 199 (41.2%) 34 (35.4%) 123 (50.6%) 356 (43.3%)
Polypharmacy (>5 medications) < 0.001
• No 367 (76.0%) 78 (81.2%) 152 (62.6%) 597 (72.6%)
• Yes 116 (24.0%) 18 (18.8%) 91 (37.4%) 225 (27.4%)
HAART duration (years) 0.001
Median (Q1, Q3) 16.1 (10.3, 20.4) 13.5 (8.5, 19.9) 18.3 (12.0, 21.1) 16.4 (10.2, 20.7)
CD4 0.401
Median (Q1, Q3) 610.0 (443.0, 826.0) 651.0 (435.5, 853.8) 618.0 (440.8, 733.8) 618.0 (437.5, 814.0)
HIV suppressed (not detectable or RNA < 50) 0.125
• No 13 (4.6%) 5 (10.4%) 3 (2.9%) 21 (4.8%)
• Yes 268 (95.4%) 43 (89.6%) 102 (97.1%) 413 (95.2%)
DUAL (InSTI + other) < 0.001
• No 424 (87.8%) NA 189 (77.8%) 709 (86.3%)
• Yes 59 (12.2%) NA 54 (22.2%) 113 (13.7%)
DUAL (InSTI + Lamivudine) < 0.001
• No 394 (81.6%) NA 242 (99.6%) 732 (89.1%)
• Yes 89 (18.4%) NA 1 (0.4%) 90 (10.9%)
DUAL (InSTI + Rilpivirine) < 0.001
• No 436 (90.3%) NA 240 (98.8%) 772 (93.9%)
• Yes 47 (9.7%) NA 3 (1.2%) 50 (6.1%)
TRIPLE (InSTI + 2 others) < 0.001
• No 207 (42.9%) 5 (5.2%) 84 (34.6%) 296 (36.0%)
• Yes 276 (57.1%) 91 (94.8%) 159 (65.4%) 526 (64.0%)
MEGA (InSTI + at least 4 others)—molecules < 0.001
• No 471 (97.5%) 91 (94.8%) 217 (89.3%) 779 (94.8%)
• Yes 12 (2.5%) 5 (5.2%) 26 (10.7%) 43 (5.2%)
Abacavir < 0.001
• No 325 (67.3%) 96 (100.0%) 216 (88.9%) 637 (77.5%)
• Yes 158 (32.7%) 0 (0.0%) 27 (11.1%) 185 (22.5%)
Single Tablet Regimen < 0.001
• No 330 (68.3%) 5 (5.2%) 243 (100.0%) 578 (70.3%)
• Yes 153 (31.7%) 91 (94.8%) 0 (0.0%) 244 (29.7%)
NA: not applicable.
https://doi.org/10.1371/journal.pone.0258533.t001
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20.4), 18.3 (12.0–21.1) and 13.5 (8.5–19.9) years in the DTG, RAL and EVG/c group respec-
tively, with significant differences among the three InSTIs (Kruskal-Wallis test, p = 0.001).
The median follow-up time, computed with KM estimator, was 12.7 months. At the end of
the follow up 29 (6.0%), 52 (21.4%) and 22 (22.9%) participants discontinued DTG, RAL and
EVG/c respectively. The median discontinuation time calculated as the time required to reach
a drug discontinuation of 50% was 29 months for EVG and 36 months for RAL while DTG
did not reach 50% discontinuation (after 36 months the proportion of participants who dis-
continued DTG was 23%). Using a log-rank test, EVG showed a significantly lower durability
than DTG (p<0.001) or RAL (p = 0.048) or both DTG and RAL (p<0.001). The curves show-
ing the proportion of participants discontinuing InSTI regimen are shown in Fig 1A. When
adjusting for age, sex, multimorbidity and abacavir usage we were still able to find a significant
difference between DTG and EVG but not between RAL and EVG (p = 0.002 and p = 0.111
respectively, Table 2).
An intriguing treatment option recently implemented thanks to several RCTs, are two drug
regimens (2DR) InSTI-based. Analyzing this treatment choice, we found that overall 526
(64.0%) of the participants received a standard triple therapy while 195 (40.4%) received DTG-
based 2DR and 58 RAL-based 2DR. Among those receiving DTG-based 2DR, for 89 (45.6%)
participant the second drug was lamivudine (3TC), for 47 (24.1%) rilpivirine (RPV), and for
59 (30.3%) other agents. Durability of InSTI-based 2DR is shown in Fig 1B (EVG/c is not
included because it is available in 3DR regimen only).
Among participants who discontinued their regimen (103) we found 0 (0%) virological fail-
ure, 59 (56.7%) simplification/deprescription, 11 (25.9%) other reasons, including 4 adverse
events and 1 participant’s preference. For the remaining 33 participants, data regarding the
reason of InSTI discontinuation are missing, although among them 4 participants changed
molecules in the InSTI class.
Discussion
This longitudinal study in geriatric PLWH demonstrated a good durability of InSTI-based reg-
imens analysed with a particularly good performance of DTG-based regimens (regardless of
accompanying drugs).
Geriatric Patients Living with HIV/AIDS (GEPPO) is a prospective observational cohort
including consecutive HIV-positive geriatric patients in care at 11 HIV clinics all over Italy
compared with a HIV-negative control group. The aim is monitoring the health status of geri-
atric PLWH as well as study how the common geriatric care model applies to PLWH [11].
The 822 participants at GEPPO cohort also enrolled in this study were long standing cART
experienced with a median history of more than 10 years of antiretroviral drugs and presenting
a good immunovirological profile. Aging is usually associated with a higher tendency to treat-
ment adherence [2] which may explain their good immunovirological profile. However, a
recent report from GEPPO Cohort showed that only the 31% experienced a normalization of
immunological profile with a significant difference between genders [12, 13].
As expected, in a cohort of people with a median age of 70 years, multimorbidity and poly-
pharmacy were common findings (42 and 27%, respectively). It is well known that these two
factors should be carefully considered when choosing an ART regimen: if virological suppres-
sion is achieved, NRTI-sparing, unboosted regimens are emerging as intriguing treatment
options as well as the possibility to simplify to dual therapy should be considered [2]. Notably,
tenofovir alafenamide should be preferred to tenofovir diproxil fumarate due to lower toxicity
on bone mineral density and renal function [2]. Moreover, in our cohort Guaraldi et al. did
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Fig 1. Curves showing the proportion of subjects discontinuing the InSTI regime. Comparison performed using
log-rank test for the whole cohort—p< 0.0001—(A), and the subgroup of patients undergoing a dual drug regimen
(B).
https://doi.org/10.1371/journal.pone.0258533.g001
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not observe a weight gain in participant switching from tenofovir diproxil fumarate to tenofo-
vir alafenamide nor from a InSTI-free cART to a DTG-based regimen [14].
The emerging interest on DTG-based 2DR has been extensively investigated in RCTs when
DTG was combined/co-formulated with RPV or 3TC [15]. These regimens, beyond virological
durability harbor pharmacokinetic benefits of low burden of DDI and single tablet regimen
(STR) convenience.
These data are confirmed in our cohort. None of the participants discontinued due to viro-
logical failure, while 56.7% for simplification/deprescription, and 25.9% for toxicity. These
data are in line with what found by Eaton et al. [9]: ART changes due to virological failure are
less and less common in recent years while most switches are due to convenience and side
effects. Moreover, the low rate of transmitted resistance-associated mutations to InSTIs and
the high genetic barrier of this class contributes explaining this result [16].
These data may also be put in the perspective of the fourth 90% target recently suggested as
outcome in the HIV treatment cascade. Switching ARV in geriatric PLWH is mainly driven by
a proactive strategy to avoid polypharmacy in a de-prescribing approach, often applied in gen-
eral geriatric population [17]. In this context, given the long durability of the prescribed regi-
men, this study contributes to generate new data regarding safety of both 3DR and 2DR InSTI
based regimen in this particular population.
EVG and RAL also showed a good durability (29 and 36 months respectively), though they
were less preferred in GEPPO cohort in comparison to DTG. A few hypotheses may be provided.
EVG is necessarily boosted with cobicistat which strongly inhibit CYP3A4 displaying a
higher EVG risk of DDIs, producing concerns in the context of polypharmacy. RAL discontin-
uation may be due to high pill burden regardless of the once a day RAL formulation which has
been recently released. To note RAL anyway showed a good durability, higher than EVG.
In geriatric PLWH deprescription options should be the standard of care. This process
implies therapy review with the goal of medication reconciliation and medication prioritiza-
tions to prevent unnecessary drug prescriptions. In this context 2DR and 3DR unboosted STR
regimens should be prioritised [18]. Recent data on STR bictegravir-based treatments in
elderly participants showed excellent efficacy and tolerability: the randomized clinical setting
support further real-life investigations [7].
Several limitations of our study should be acknowledged: missing data, short follow up,
only one time-point per year, and the observational design, unable sometimes to evaluate the
clinical decisions.
Conclusion
Although the three InSTI considered showed some differences in this geriatric cohort of
patients, all of them had a durability of more than two years with no virological failures. In
Table 2. Results obtained applying a Cox regression to test the difference in time to discontinuation among InSTI
group adjusting for age, sex, multimorbidity and abacavir use.
Predictors Estimates CI p
InSTI: DTG vs EVG 0.24 0.09–0.59 0.002
InSTI: RAL vs EVG 0.43 0.15–1.21 0.111
Age 1.00 0.97–1.04 0.920
Sex: Male vs Female 1.11 0.68–1.82 0.663
Multimorbidity: Yes vs No 0.67 0.44–1.02 0.064
Abacavir: Yes vs No 0.85 0.41–1.75 0.658
STR: Yes vs No 0.63 0.25–1.57 0.319
https://doi.org/10.1371/journal.pone.0258533.t002
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geriatric patients such as those enrolled in the GEPPO cohort 2DR and 3DR unboosted STR
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